Matches in SemOpenAlex for { <https://semopenalex.org/work/W4256376103> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4256376103 endingPage "563" @default.
- W4256376103 startingPage "556" @default.
- W4256376103 abstract "The aim of the present study was to assess the beta cell response to glimepiride, administered orally, during and following a hyperglycaemic clamp in 14 NIDDM patients (7 males), aged 62.5 (St. Dev. 7.7) years with a body mass index of 27.3 (2.8) kg m−2 and HbAlc of 7.0 (0.7) % at baseline, in a placebo controlled study. All patients were on stable treatment with a second generation sulphonylurea for at least 8 weeks prior to randomization and received placebo (P) or 5 mg glimepiride (G) daily for 7 days and 10 mg prior to a hyperglycaemic clamp (10.9 mmol l−1 for 60 min, preceded by i.v. insulin infusion to stablize fasting blood glucose levels at 4.0 mmol l−1). The clamp was followed by an observation period of 2 h in 5 subjects and 3.5 h in the next 9 subjects, during which blood glucose and plasma insulin, C-peptide and proinsulin levels were measured at regular intervals to determine the effect of glimepiride on the interaction between changes in glycaemia and plasma levels of beta cell products. Neither G nor P elicited a first phase insulin response. Areas under plasma insulin curve during the 1 h hyperglycaemic clamp were 94.2 (39.5) vs 69.1 (26.5) pmol.h l−1 in G and P clamps, respectively (p = 0.002). Total areas (AUC) under the plasma insulin curve were 377 (145) vs 271 (113) pmol.h l−1 in G and P clamps (< 0.05). Total AUCs of C-peptide were 309 (96) and 259 (102 pmol.h.−1, in G and P clamps, respectively, p = 0.01. Total AUCs of proinsulin were 176 (77) versus 119 (56) pmol.h l−1 in G and P clamps, respectively, p = 0.004. Five hours after G and P administration blood glucose levels were 4.7) 92.1) mmol−1 in the G clamp vs 6.2 (1.9) mmol l−1 in the P clamp (p = 0.001). The number of hypoglycaemic events (blood glucose < 3.0 mmol l−1) in the 3.5 h observation period was 3 in G clamps vs 0 in P clamps (p = ns). In conclusion, glimepiride stimulates the second phase insulin and proinsulin secretion. The lowering of blood glucose levels is not accompanied by a commensurate inhibition of the insulin secretion. Further studies are required to compare this new drug with currently available oral hypoglycaemic agents, with respect to glycaemic control and the risk of hypoglycaemia. © 1997 John Wiley & Sons, Ltd." @default.
- W4256376103 created "2022-05-12" @default.
- W4256376103 creator A5025440686 @default.
- W4256376103 creator A5026570262 @default.
- W4256376103 creator A5030560836 @default.
- W4256376103 creator A5039956732 @default.
- W4256376103 creator A5046449923 @default.
- W4256376103 creator A5057642588 @default.
- W4256376103 date "1997-07-01" @default.
- W4256376103 modified "2023-09-26" @default.
- W4256376103 title "Beta Cell Response to Oral Glimepiride Administration During and Following a Hyperglycaemic Clamp in NIDDM Patients" @default.
- W4256376103 doi "https://doi.org/10.1002/(sici)1096-9136(199707)14:7<556::aid-dia389>3.3.co;2-y" @default.
- W4256376103 hasPublicationYear "1997" @default.
- W4256376103 type Work @default.
- W4256376103 citedByCount "0" @default.
- W4256376103 crossrefType "journal-article" @default.
- W4256376103 hasAuthorship W4256376103A5025440686 @default.
- W4256376103 hasAuthorship W4256376103A5026570262 @default.
- W4256376103 hasAuthorship W4256376103A5030560836 @default.
- W4256376103 hasAuthorship W4256376103A5039956732 @default.
- W4256376103 hasAuthorship W4256376103A5046449923 @default.
- W4256376103 hasAuthorship W4256376103A5057642588 @default.
- W4256376103 hasConcept C126322002 @default.
- W4256376103 hasConcept C134018914 @default.
- W4256376103 hasConcept C142724271 @default.
- W4256376103 hasConcept C204787440 @default.
- W4256376103 hasConcept C27081682 @default.
- W4256376103 hasConcept C2776307423 @default.
- W4256376103 hasConcept C2777391703 @default.
- W4256376103 hasConcept C2778808658 @default.
- W4256376103 hasConcept C2779306644 @default.
- W4256376103 hasConcept C2780323712 @default.
- W4256376103 hasConcept C2780352109 @default.
- W4256376103 hasConcept C71924100 @default.
- W4256376103 hasConcept C76318530 @default.
- W4256376103 hasConcept C90061646 @default.
- W4256376103 hasConceptScore W4256376103C126322002 @default.
- W4256376103 hasConceptScore W4256376103C134018914 @default.
- W4256376103 hasConceptScore W4256376103C142724271 @default.
- W4256376103 hasConceptScore W4256376103C204787440 @default.
- W4256376103 hasConceptScore W4256376103C27081682 @default.
- W4256376103 hasConceptScore W4256376103C2776307423 @default.
- W4256376103 hasConceptScore W4256376103C2777391703 @default.
- W4256376103 hasConceptScore W4256376103C2778808658 @default.
- W4256376103 hasConceptScore W4256376103C2779306644 @default.
- W4256376103 hasConceptScore W4256376103C2780323712 @default.
- W4256376103 hasConceptScore W4256376103C2780352109 @default.
- W4256376103 hasConceptScore W4256376103C71924100 @default.
- W4256376103 hasConceptScore W4256376103C76318530 @default.
- W4256376103 hasConceptScore W4256376103C90061646 @default.
- W4256376103 hasIssue "7" @default.
- W4256376103 hasLocation W42563761031 @default.
- W4256376103 hasOpenAccess W4256376103 @default.
- W4256376103 hasPrimaryLocation W42563761031 @default.
- W4256376103 hasRelatedWork W1985226700 @default.
- W4256376103 hasRelatedWork W1988357167 @default.
- W4256376103 hasRelatedWork W2009357037 @default.
- W4256376103 hasRelatedWork W2012273189 @default.
- W4256376103 hasRelatedWork W2040934062 @default.
- W4256376103 hasRelatedWork W2063154555 @default.
- W4256376103 hasRelatedWork W2141287906 @default.
- W4256376103 hasRelatedWork W2151588256 @default.
- W4256376103 hasRelatedWork W2161160210 @default.
- W4256376103 hasRelatedWork W4232141058 @default.
- W4256376103 hasVolume "14" @default.
- W4256376103 isParatext "false" @default.
- W4256376103 isRetracted "false" @default.
- W4256376103 workType "article" @default.